Protagonist (PTGX) | Financial Analysis & Statements
Protagonist Therapeutics Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
7.4M
Operating Income
-50.4M
-677.09%
Net Income
-44.4M
-596.80%
Balance Sheet Metrics
Total Assets
668.2M
Total Liabilities
53.5M
Shareholders Equity
614.7M
Debt to Equity
0.09
Cash Flow Metrics
Operating Cash Flow
-40.7M
Free Cash Flow
-37.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Protagonist Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 46.0M | 434.4M | 60.0M | 26.6M | 27.4M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 159.3M | 138.1M | 120.2M | 126.2M | 126.0M |
| Selling, General & Administrative | 44.9M | 43.5M | 33.5M | 31.7M | 27.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 204.1M | 181.6M | 153.7M | 158.0M | 153.2M |
| Operating Income | -158.1M | 252.8M | -93.7M | -131.4M | -125.8M |
| Operating Margin % | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% |
| Non-Operating Items | |||||
| Interest Income | 28.8M | 26.3M | 14.9M | 4.1M | 443.0K |
| Interest Expense | - | - | - | 0 | 0 |
| Other Non-Operating Income | 27.0K | 250.0K | -201.0K | -80.0K | -149.0K |
| Pre-tax Income | -129.3M | 279.4M | -79.0M | -127.4M | -125.6M |
| Income Tax | 838.0K | 4.2M | - | 0 | 0 |
| Effective Tax Rate % | 0.0% | 1.5% | 0.0% | 0.0% | 0.0% |
| Net Income | -130.1M | 275.2M | -79.0M | -127.4M | -125.6M |
| Net Margin % | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% |
| Key Metrics | |||||
| EBITDA | -156.8M | 255.7M | -90.3M | -128.0M | -123.1M |
| EPS (Basic) | $-2.05 | $4.47 | $-1.39 | $-2.60 | $-2.71 |
| EPS (Diluted) | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 |
| Basic Shares Outstanding | 63573048 | 61566989 | 56763559 | 49042232 | 46322910 |
| Diluted Shares Outstanding | 63573048 | 61566989 | 56763559 | 49042232 | 46322910 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Protagonist Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 128.4M | 97.2M | 186.7M | 125.7M | 123.7M |
| Short-term Investments | 439.0M | 321.7M | 154.9M | 111.6M | 203.2M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | - | 42.0K | 975.0K |
| Total Current Assets | 577.6M | 591.6M | 355.6M | 243.1M | 340.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 15.6M | 15.8M | 6.3M | 7.9M | 9.1M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 287.0K | 225.0K | 225.0K | 225.0K | 225.0K |
| Total Non-Current Assets | 90.6M | 153.1M | 2.4M | 4.9M | 7.0M |
| Total Assets | 668.2M | 744.7M | 358.0M | 247.9M | 347.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 5.3M | 1.6M | 772.0K | 3.6M | 1.6M |
| Short-term Debt | 2.3M | 510.0K | 1.1M | 2.5M | 2.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 45.4M | 47.4M | 21.3M | 31.2M | 44.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 8.0M | 10.4M | 0 | 1.1M | 3.7M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 8.0M | 22.0M | 0 | 1.1M | 3.7M |
| Total Liabilities | 53.5M | 69.4M | 21.3M | 32.3M | 47.7M |
| Equity | |||||
| Common Stock | 1.0K | 1.0K | 1.0K | 0 | 0 |
| Retained Earnings | -470.7M | -340.5M | -615.7M | -536.8M | -409.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 614.7M | 675.3M | 336.7M | 215.6M | 300.0M |
| Key Metrics | |||||
| Total Debt | 10.3M | 10.9M | 1.1M | 3.7M | 5.9M |
| Working Capital | 532.1M | 544.2M | 334.3M | 211.9M | 296.7M |
Balance Sheet Composition
Protagonist Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -130.1M | 275.2M | -79.0M | -127.4M | -125.6M |
| Depreciation & Amortization | 1.3M | 2.9M | 3.3M | 3.4M | 2.8M |
| Stock-Based Compensation | 46.0M | 37.6M | 29.3M | 24.2M | 16.4M |
| Working Capital Changes | 146.7M | -125.8M | -15.6M | 2.0M | -17.4M |
| Operating Cash Flow | 65.4M | 189.8M | -61.8M | -97.8M | -123.7M |
| Investing Activities | |||||
| Capital Expenditures | -1.6M | -1.4M | -609.0K | -795.0K | -1.1M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -546.6M | -621.7M | -191.0M | -214.9M | -286.6M |
| Investment Sales | 498.8M | 323.6M | 152.4M | 307.1M | 271.8M |
| Investing Cash Flow | -49.3M | -299.5M | -39.3M | 91.5M | -15.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | 0 |
| Debt Repayment | - | - | - | 0 | 0 |
| Financing Cash Flow | -479.0K | -600.0K | 131.3M | 14.4M | 123.6M |
| Free Cash Flow | 56.1M | 182.8M | -70.8M | -108.9M | -109.0M |
| Net Change in Cash | 15.6M | -110.3M | 30.3M | 8.1M | -16.0M |
Cash Flow Trend
Protagonist Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
139.52
Forward P/E
-244.06
Price to Book
10.79
Price to Sales
146.96
PEG Ratio
-1.05
Profitability Ratios
Profit Margin
-282.83%
Operating Margin
-677.09%
Return on Equity
-20.18%
Return on Assets
-13.99%
Financial Health
Current Ratio
12.71
Debt to Equity
1.68
Beta
2.11
Per Share Data
EPS (TTM)
$-2.05
Book Value per Share
$9.82
Revenue per Share
$0.72
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PTGX | 6.8B | 139.52 | 10.79 | -20.18% | -282.83% | 1.68 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Arrowhead | 10.4B | 46.50 | 17.98 | 75.50% | 18.54% | 124.07 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
Financial data is updated regularly. All figures are in the company's reporting currency.






